Skip to content
All research profiles

Prescription immunosuppressant / longevity

Sirolimus

Prepared by the ezGLP team. Sources last checked .

Also known as Rapamycin

Routes represented in the knowledgebase: Oral.

Educational overview

FDA-approved immunosuppressant; anti-aging use is off-label and has not established lifespan or healthspan benefit in humans. Infection and malignancy risks are substantial.

Category
Prescription immunosuppressant / longevity
Routes represented
Oral
Storage context
Follow the product or pharmacy label; requirements vary by route and formulation.
Authoritative overview

Published literature

No validated PubMed or DOI link is currently curated for this entry.

Safety evidence

Common or reported: edema, high triglycerides or cholesterol, hypertension, diarrhea, nausea, stomatitis, anemia.

Serious or important: serious infection, impaired wound healing, renal dysfunction, interstitial lung disease, thrombotic microangiopathy, embryo-fetal toxicity.

Safety evidence source

Interaction evidence

These are general, pairwise evidence notes. Green identifies the potential-synergy category, while Lv3/Lv2/Lv1 communicates evidence strength; it does not guarantee benefit or cancel a safety warning.

With strong CYP3A4/P-gp inhibitors

Safety flag

Strong CYP3A4 or P-gp inhibition can markedly increase sirolimus exposure and toxicity.

Interaction evidence source

With strong CYP3A4/P-gp inducers

Safety flag

Strong CYP3A4 or P-gp induction can reduce sirolimus exposure and cause treatment failure.

Interaction evidence source

With live vaccines

Safety flag

Immunosuppression can permit vaccine-related infection and reduce vaccine response.

Interaction evidence source

Summarised from published literature for reference only, with citations to the source. Evidence is graded as reported and is not a recommendation to combine, dose, or use any compound.

For personal tracking and education only. Not medical advice, diagnosis, or treatment, and not a medical device. Peptides may be prescription-only or unapproved where you live — consult a licensed healthcare professional.